Richard Onyett is Vice President of Business Development at ADC Therapeutics.
Mr. Onyett has over 40 years of experience in the pharmaceutical and biotech industries. Prior to joining ADC Therapeutics, Mr. Onyett was Commercial Director at Spirogen Limited, responsible for business development with respect to licensing of PBD cytotoxin payload technology to major pharma and specialized biotech companies worldwide.
Prior to Spirogen, Mr. Onyett ran his own successful commercial development consultancy and subsequently served as Senior Vice President of Business or Corporate Development for a number of biotech companies based in the US, Europe, and UK, including KuDOS Pharmaceuticals, where he was responsible for the BD strategy and activity that lead to the sale of KuDOS Pharmaceuticals to AstraZeneca in 2006. Mr. Onyett began his career as International Product Manager with ICI Pharmaceuticals (now AstraZeneca) and subsequently as Director of Business Development for SmithKline and French (now GlaxoSmithKline).
Mr. Onyett graduated with a B. Sc. (hons.) in Biological Sciences from the University of Nottingham, England and a M.Sc. in General Virology from the University of Birmingham, England.